23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells‘1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6, and inducing Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector functionPhase 1 clinical study in patients with solid tumors to commence in H1 2024The target for ‘1473 was discovered through 23andMe's proprietary research platform, the world's largest recontactable database of de-identified h ...